JP2012526848A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2012526848A5 JP2012526848A5 JP2012511019A JP2012511019A JP2012526848A5 JP 2012526848 A5 JP2012526848 A5 JP 2012526848A5 JP 2012511019 A JP2012511019 A JP 2012511019A JP 2012511019 A JP2012511019 A JP 2012511019A JP 2012526848 A5 JP2012526848 A5 JP 2012526848A5
- Authority
- JP
- Japan
- Prior art keywords
- ranolazine
- composition
- nervous system
- central nervous
- effective amount
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17817009P | 2009-05-14 | 2009-05-14 | |
| US61/178,170 | 2009-05-14 | ||
| US27939509P | 2009-10-20 | 2009-10-20 | |
| US61/279,395 | 2009-10-20 | ||
| PCT/US2010/034778 WO2010132696A1 (en) | 2009-05-14 | 2010-05-13 | Ranolazine for the treatment of cns disorders |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2012526848A JP2012526848A (ja) | 2012-11-01 |
| JP2012526848A5 true JP2012526848A5 (enExample) | 2013-06-27 |
Family
ID=42262042
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2012511019A Pending JP2012526848A (ja) | 2009-05-14 | 2010-05-13 | Ｃｎｓ障害の治療のためのラノラジン |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20100292217A1 (enExample) |
| EP (1) | EP2429526A1 (enExample) |
| JP (1) | JP2012526848A (enExample) |
| AU (1) | AU2010248948A1 (enExample) |
| CA (1) | CA2761771A1 (enExample) |
| MX (1) | MX2011012140A (enExample) |
| WO (1) | WO2010132696A1 (enExample) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2003248558B8 (en) * | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| CA2689633A1 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| US8652527B1 (en) | 2013-03-13 | 2014-02-18 | Upsher-Smith Laboratories, Inc | Extended-release topiramate capsules |
| US9101545B2 (en) | 2013-03-15 | 2015-08-11 | Upsher-Smith Laboratories, Inc. | Extended-release topiramate capsules |
| CN113318111B (zh) * | 2021-06-21 | 2026-02-03 | 浙江大学 | Nav1.1激动剂在制备治疗自闭症的药物中的应用 |
| WO2025078664A1 (en) * | 2023-10-12 | 2025-04-17 | Celex Oncology Innovations Limited | Treatment of metastatic or invasive brain cancer |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) * | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4173626A (en) * | 1978-12-11 | 1979-11-06 | Merck & Co., Inc. | Sustained release indomethacin |
| US4326525A (en) * | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) * | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) * | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US4992445A (en) * | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US5001139A (en) * | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4902514A (en) * | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| ES2177601T3 (es) * | 1989-06-23 | 2002-12-16 | Syntex Llc | Ranolazina y pepeerazinas relacionadas para uso en el tratamiento de estados de choque. . |
| US5455045A (en) * | 1993-05-13 | 1995-10-03 | Syntex (U.S.A.) Inc. | High dose formulations |
| DE69429524T2 (de) * | 1993-09-24 | 2002-08-08 | The University Of British Columbia, Vancouver | Aminocyclohexylester und ihre anwendung |
| ZA953078B (en) * | 1994-04-28 | 1996-01-05 | Alza Corp | Effective therapy for epilepsies |
| US20030077229A1 (en) * | 1997-10-01 | 2003-04-24 | Dugger Harry A. | Buccal, polar and non-polar spray or capsule containing cardiovascular or renal drugs |
| US6541479B1 (en) * | 1997-12-02 | 2003-04-01 | Massachusetts College Of Pharmacy | Calcium channel blockers |
| US6303607B1 (en) * | 1998-09-10 | 2001-10-16 | Cv Therapeutics, Inc. | Method for administering a sustained release ranolanolazine formulation |
| US6479496B1 (en) * | 1998-09-10 | 2002-11-12 | Cv Therapeutics, Inc. | Methods for treating angina with ranolazine |
| NZ520780A (en) * | 2000-02-18 | 2006-04-28 | Cv Therapeutics Inc | Partial fatty acid oxidation inhibitors in the treatment of congestive heart failure |
| US6677336B2 (en) * | 2000-02-22 | 2004-01-13 | Cv Therapeutics, Inc. | Substituted piperazine compounds |
| AU2001263230B2 (en) * | 2000-05-19 | 2005-03-10 | Amylin Pharmaceuticals, Llc | Treatment of acute coronary syndrome with glp-1 |
| WO2002007716A2 (en) * | 2000-07-21 | 2002-01-31 | Cv Therapeutics, Inc. | Method for treating angina |
| US6573264B1 (en) * | 2000-10-23 | 2003-06-03 | Cv Therapeutics, Inc. | Heteroaryl alkyl piperazine derivatives |
| MXPA04000565A (es) * | 2001-07-19 | 2005-06-17 | Cv Therapeutics Inc | Compuestos de piperazina sustituidos y su uso como inhibidores de oxidacion de acidos grasos. |
| US20030220344A1 (en) * | 2002-04-04 | 2003-11-27 | Luiz Belardinelli | Method of treating arrhythmias |
| US20080109040A1 (en) * | 2002-04-04 | 2008-05-08 | Luiz Belardinelli | Method of treating arrhythmias |
| US8822473B2 (en) * | 2002-05-21 | 2014-09-02 | Gilead Sciences, Inc. | Method of treating diabetes |
| AU2003248558B8 (en) * | 2002-05-21 | 2009-07-09 | Gilead Sciences, Inc. | Method of treating diabetes |
| MX2007005367A (es) * | 2004-11-09 | 2007-06-18 | Cv Therapeutics Inc | Uso de ranolazina en combinacion con por lo menos un agente de remodelacion para revertir la remodelacion ventricular izquierda en el tratamiento de la insuficiencia cardiaca. |
| MX2007008162A (es) * | 2005-01-06 | 2007-07-24 | Cv Therapeutics Inc | Formulaciones farmaceuticas de liberacion prolongada que contienen ranolazina. |
| US20090312340A1 (en) * | 2007-02-13 | 2009-12-17 | Whedy Wang | Use of ranolazine for the treatment of cardiovascular diseases |
| CA2678272A1 (en) * | 2007-02-13 | 2008-10-02 | Cv Therapeutics, Inc. | Use of ranolazine for the treatment of cardiovascular diseases |
| JP2010518171A (ja) * | 2007-02-13 | 2010-05-27 | ギリアード・パロ・アルト・インコーポレイテッド | 非冠微小血管疾患の処置のためのラノラジンの使用 |
| US20090111826A1 (en) * | 2007-02-13 | 2009-04-30 | Louis Lange | Use of ranolazine for the treatment of cardiovascular diseases |
| EP2117549A1 (en) * | 2007-02-13 | 2009-11-18 | CV Therapeutics Inc. | Use of ranolazine for the treatment of coronary microvascular diseases |
| WO2008116083A1 (en) * | 2007-03-22 | 2008-09-25 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| CA2689633A1 (en) * | 2007-05-31 | 2008-12-11 | Cv Therapeutics, Inc. | Use of ranolazine for elevated brain-type natriuretic peptide |
| BRPI0908428A2 (pt) * | 2008-02-06 | 2015-12-08 | Gilead Sciences Inc | uso de ranozalina para tratar a dor. |
| US20090247535A1 (en) * | 2008-03-26 | 2009-10-01 | Duke University | Use of ranolazine for non-cardiovascular disorders |
| JP2012502047A (ja) * | 2008-09-04 | 2012-01-26 | ギリアード サイエンシーズ， インコーポレイテッド | 心房細動を治療する方法 |
| WO2010068461A1 (en) * | 2008-11-25 | 2010-06-17 | Gilead Palo Alto, Inc. | Co-administration of ranolazine and cardiac glycosides |
-
2010
- 2010-05-13 MX MX2011012140A patent/MX2011012140A/es active IP Right Grant
- 2010-05-13 EP EP10720094A patent/EP2429526A1/en not_active Withdrawn
- 2010-05-13 AU AU2010248948A patent/AU2010248948A1/en not_active Abandoned
- 2010-05-13 WO PCT/US2010/034778 patent/WO2010132696A1/en not_active Ceased
- 2010-05-13 US US12/779,753 patent/US20100292217A1/en not_active Abandoned
- 2010-05-13 CA CA2761771A patent/CA2761771A1/en not_active Abandoned
- 2010-05-13 JP JP2012511019A patent/JP2012526848A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6918724B2 (ja) | 急性骨髄性白血病（ａｍｌ）のための新規併用治療 | |
| EP3658538B1 (en) | Compounds and compositions for treating conditions associated with nlrp activity | |
| RU2014111478A (ru) | Лечение с использованием ацетата эсликарбазепина или эсликарбазепина | |
| JOP20210017A1 (ar) | مثبطات جسيم التهابي nlrp3 | |
| EA201490279A1 (ru) | Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения | |
| PH12012501480A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| UY32599A (es) | Formulación oral sólida de abt-263 | |
| JP2010531879A5 (enExample) | ||
| PH12014500239A1 (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| PH12014500371A1 (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
| ME02179B (me) | Metoda za lečenje atrijalne fibrilacije | |
| KR20160004299A (ko) | 옥사바이시클로헵탄류 및 옥사바이시클로헵텐류의 제형 | |
| JP2012111764A5 (enExample) | ||
| JP2013518914A5 (enExample) | ||
| EA201492010A1 (ru) | Применение высокой дозы лахинимода для лечения рассеянного склероза | |
| JP2017531043A5 (enExample) | ||
| JP2016501219A5 (enExample) | ||
| US20070004727A1 (en) | Use of compounds for the prevention of drug-induced cell toxicity | |
| Dantio et al. | Seizures in brain tumors: pathogenesis, risk factors and management | |
| RU2005133665A (ru) | Применение производных 10-гидрокси-10,11-дигидрокарбамазепина для лечения аффективных расстройств | |
| RU2015113031A (ru) | Использование 3-n-бутил изоиндолин кетонов при приготовлении лекарственных средств для профилактики и лечения церебрального инфаркта | |
| JP2018529747A5 (enExample) | ||
| JP5341037B2 (ja) | 双極性障害を処置するための医薬を得るためのアゴメラチンの使用 | |
| Cheson et al. | Bendamustine induced neurotoxicity |